GUIDELINES FOR THE USE OF CLOZAPINE IN INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES
Saved in:
SABAAWI, M, ET AL., GUIDELINES FOR THE USE OF CLOZAPINE IN INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES. Research in Developmental Disabilities, Vol. 27, no. 3 (2006), p. 309-336.
Ref.
140748
Location:
SIIS R.775 Archivo
Palabras clave:
Cuestionarios, Discapacidad intelectual, Efectos, Efectos no deseados, Escalas, Evaluación, Fármacos, Psicótropos, Recomendaciones, Tratamiento médico
Cuestionarios, Discapacidad intelectual, Efectos, Efectos no deseados, Escalas, Evaluación, Fármacos, Psicótropos, Recomendaciones, Tratamiento médico
Similar Items: GUIDELINES FOR THE USE OF CLOZAPINE IN INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES
- PRACTICAL GUIDELINES FOR THE USE OF NEW GENERATION ANTIPSYCHOTIC DRUGS (EXCEPT CLOZAPINE) IN ADULT INDIVIDUALS WITH INTELLECTUAL DISABILITIES
- GUIDELINES FOR THE USE OF PSYCHOTROPIC MEDICATION IN INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES
- THE USE OF CLOZAPINE AMONG INDIVIDUALS WITH INTELLECTUAL DISABILITY: A REVIEW
- CLOZAPINE IN THREE INDIVIDUALS WITH MILD MENTAL RETARDATION AND TREATMENT-REFRACTORY PSICHIATRIC DISORDERS
- BENZODIAZEPINES: GOOD PRACTICE GUIDELINES FOR CLINICIANS
- AN EXAMINATION OF PSYCHOTROPIC MEDICATION SIDE EFFECTS: DOES TAKING A GREATER NUMBER OF PSYCHOTROPIC MEDICATIONS FROM DIFFERENT CLASSES AFFECT PRESENTATION OF SIDE EFFECTS IN ADULTS WITH ID?